Advanced Enzymes reported a 2% year-over-year increase in revenue for Q3 FY26, reaching ₹1,719 million. Despite a 7% sequential decline, nine-month revenue grew by 15% to ₹5,424 million. The animal nutrition segment saw strong growth, while human nutrition experienced a slight decrease. The company continues to invest in R&D and explore strategic acquisitions to bolster its B2C business and expand geographically.
Q3 FY26 Financial Highlights
Advanced Enzymes Technologies Ltd. announced its unaudited financial results for the third quarter (Q3) and nine months (9M) ended December 2025. Consolidated revenue for Q3 FY26 stood at ₹1,719 million, a 2% increase compared to ₹1,691 million in Q3 FY25. However, this represents a 7% decrease from the previous quarter (Q2 FY26).
Profit after tax (PAT) for Q3 FY26 grew by 11% to ₹432 million, compared to ₹389 million in Q3 FY25. Earnings Per Share (EPS) increased to ₹3.80 from ₹3.36 in the same quarter last year.
Nine-Month Performance
For the nine months ended December 2025, the company reported a 15% increase in revenue, reaching ₹5,424 million, up from ₹4,697 million in the corresponding period of the previous year. Profit after tax for the 9M period grew by 20% to ₹1,284 million. EPS for the nine months stood at ₹11.24.
Segmental Performance
Human Nutrition: Revenue decreased by 6% to ₹962 million in Q3 FY26. However, for the 9M period, this segment grew by 12%.
Animal Nutrition: Demonstrated strong growth, with a 22% increase in Q3 FY26 to ₹241 million. The 9M growth was even stronger at 26%.
Bio-Processing: Recorded a 13% increase in Q3 FY26, reaching ₹361 million. This segment also showed a 15% growth for the 9M period.
Geographical Performance
Domestic sales accounted for 47% of revenue in Q3 FY26, while international sales contributed the remaining 53%. Asia (excluding India) reported a growth of 14%.
Strategic Outlook
Advanced Enzymes is focusing on expanding its product portfolio, particularly in probiotics. The company is also investing in R&D and exploring strategic acquisition opportunities.
Source: BSE
